Interpace Biosciences Inc (IDXG)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2015 | 12-2014 | 12-2013 | 12-2012 | 12-2011 | |
| Sales | 9,432 | 1,474 | 146,534 | 126,899 | 157,291 |
| Cost of Goods | 6,910 | 1,268 | 123,029 | 100,039 | 124,820 |
| Gross Profit | 2,522 | 206 | 23,505 | 26,860 | 32,471 |
| Operating Expenses | 43,840 | 18,300 | 24,971 | 52,131 | 37,993 |
| Operating Income | -40,408 | -17,826 | -1,437 | -25,232 | -4,702 |
| Interest Expense | 3,705 | 602 | 0 | 0 | 0 |
| Other Income | -93 | -68 | -59 | -28 | -14 |
| Pre-tax Income | -44,206 | -18,496 | -1,496 | -25,260 | -4,716 |
| Income Tax | -13,136 | -5,030 | 180 | 208 | -939 |
| Net Income Continuous | -31,070 | -13,466 | -1,676 | -25,468 | -3,777 |
| Net Income Discontinuous | 19,714 | -2,607 | -2,889 | -59 | -8,137 |
| Net Income | $-11,356 | $-16,073 | $-4,565 | $-25,527 | $-11,914 |
| EPS Basic Total Ops | -73.40 | -108.00 | -31.00 | -175.00 | -83.00 |
| EPS Basic Continuous Ops | -200.80 | -90.00 | -11.00 | -175.00 | -26.00 |
| EPS Basic Discontinuous Ops | 127.40 | -18.00 | -20.00 | -0.40 | -57.00 |
| EPS Diluted Total Ops | -73.40 | -108.00 | -31.00 | -175.00 | -83.00 |
| EPS Diluted Continuous Ops | -200.80 | -90.00 | -11.00 | -175.00 | -26.00 |
| EPS Diluted Discontinuous Ops | 127.40 | -18.00 | -20.00 | -0.40 | -57.00 |
| EBITDA(a) | $-19,712 | $-15,435 | $-12 | $-23,198 | $-1,656 |